| [1] |
Gibbins KJ, Tebo AE, Nielsen SK, et al. Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study [J]. Lupus, 2018, 27(12): 1903-1910.
|
| [2] |
Heydarlou H, Eghabl-Fard S, Ahmadi M, et al. Investigation of follicular helper T cells, as a novel player, in preeclampsia [J]. J Cell Biochem, 2019, 120(3): 3845-3852.
|
| [3] |
Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology [J]. Nat Rev Nephrol, 2014, 10(8): 466-480.
|
| [4] |
谢幸，孔北华，段涛, 等. 妇产科学 [M]. 9版. 北京: 人民卫生出版社, 2018: 83-91.
|
| [5] |
Truong G, Guanzon D, Kinhal V, et al. Oxygen tension regulates the miRNA profile and bioactivity of exosomes released from extravillous trophoblast cells - Liquid biopsies for monitoring complications of pregnancy [J]. PLoS One, 2017, 12(3): e0174514.
|
| [6] |
Tong M, Johansson C, Xiao F, et al. Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia [J]. Sci Rep, 2017, 7(1): 16556.
|
| [7] |
Craici IM, Wagner SJ, Weissgerber TL, et al. Advances in the pathophysiology of pre-eclampsia and related podocyte injury [J]. Kidney Int, 2014, 86(2): 275-285.
|
| [8] |
Matsubara K, Higaki T, Matsubara Y, et al. Nitric Oxide and Reactive Oxygen Species in the Pathogenesis of Preeclampsia [J]. Int J Mol Sci, 2015, 16(3): 4600-4614.
|
| [9] |
Adu-Bonsaffoh K, Antwi DA, Gyan B, et al. Endothelial dysfunction in the pathogenesis of pre-eclampsia in Ghanaian women [J]. BMC Physiol, 2017, 17(1): 5.
|
| [10] |
Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia [J]. Nat Med, 2006, 12(6): 642-649.
|
| [11] |
Zeisler H, Llurba E, Chantraine FJ, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting [J]. Ultrasound Obstet Gynecol, 2019, 53(3): 367-375.
|
| [12] |
Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study [J]. Am J Obstet Gynecol, 2016, 214(1): 108.e1-108.e14.
|
| [13] |
Mineo C. Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis [J]. Curr Rheumatol Rep, 2013, 15(5): 324.
|
| [14] |
McCarthy FP, Kingdom JC, Kenny LC, et al. Animal models of preeclampsia; uses and limitations [J]. Placenta, 2011, 32(6): 413-419.
|
| [15] |
Erpenbeck L, Chowdhury CS, Zsengeller ZK, et al. PAD4 Deficiency Decreases Inflammation and Susceptibility to Pregnancy Loss in a Mouse Model [J]. Biol Reprod, 2016, 95(6): 132.
|
| [16] |
Giaglis S, Stoikou M, Grimolizzi F, et al. Neutrophil migration into the placenta: Good, bad or deadly? [J]. Cell Adhesion & Migration, 2016, 10(1-2): 208-225.
|
| [17] |
Lip SV, Boekschoten MV, Hooiveld GJ, et al. Early-onset preeclampsia, plasma microRNAs and endothelial cell function [J]. Am J Obstet Gynecol, 2019, 12(2): 98-106.
|
| [18] |
Perez-Sanchez C, Arias-de la Rosa I, Aguirre MA, et al. Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome [J]. Haematologica, 2018, 103(5): 908-918.
|
| [19] |
Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results [J]. Lupus science & medicine, 2016, 3(1): e000131.
|
| [20] |
Lazzaroni MG, Andreoli L, Chighizola CB, et al. Risk factors for adverse pregnancy outcome in antiphospholipid antibodies carriers: Results from a multicenter italian cohort over 20 years of experience [J]. Ann Rheum Dis, 2017, 76(70): 1-70.
|
| [21] |
Do Prado AD, Piovesan DM, Staub HL, et al. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis [J]. Obstet Gynecol, 2010, 116(6): 1433-1443.
|
| [22] |
Ferrer-Oliveras R, Llurba E, Cabero-Roura L, et al. Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets [J]. Lupus, 2012, 21(3): 257-263.
|
| [23] |
Ding X, Yang Z, Han Y, et al. Long-chain fatty acid oxidation changes in a beta2 glycoprotein I-induced preeclampsia-like mouse model [J]. Placenta, 2014, 35(6): 392-397.
|
| [24] |
Skeith L, Abou-Nassar KE, Walker M, et al. Are Anti-2 Glycoprotein 1 Antibodies Associated with Placenta-Mediated Pregnancy Complications? A Nested Case-Control Study [J]. Am J Perinatol, 2018, 35(11): 1093-1099.
|
| [25] |
张文. 抗磷脂综合征治疗进展 [J]. 中国实用内科杂志, 2017, 37(2): 120-123.
|
| [26] |
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia [J]. N Engl J Med, 2017, 377(7): 613-622.
|
| [27] |
Rolnik DL, O′Gorman N, Roberge S, et al. Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation [J]. Ultrasound Obstet Gynecol, 2017, 50(5): 551-556.
|
| [28] |
Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis [J]. Am J Obstet Gynecol, 2017, 216(2): 110-20. e6.
|
| [29] |
马晓彬. 低剂量阿司匹林预防高危孕妇子病前期的临床价值 [J]. 中国医药指南, 2019, 17(7): 79-80.
|
| [30] |
McLaughlin K, Baczyk D, Potts A, et al. Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia [J]. Hypertension, 2017, 69(1): 180-188.
|
| [31] |
Roberge S, Demers S, Nicolaides KH, et al. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis [J]. Ultrasound Obstet Gynecol, 2016, 47(5): 548-553.
|
| [32] |
Lecarpentier E, Gris JC, Cochery-Nouvellon E, et al. Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis [J]. Obstet Gynecol, 2018, 131(1): 63-69.
|
| [33] |
Van Hoorn ME, Hague WM, van Pampus MG, et al. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT [J]. Eur J Obstet Gynecol Reprod Biol, 2016, 197: 168-173.
|
| [34] |
Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial [J]. Am J Obstet Gynecol, 2017, 216(3): 296. e1-e14.
|
| [35] |
Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases [J]. Autoimmun Rev, 2019, 18(4): 406-414.
|
| [36] |
Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies [J]. Semin Thromb Hemost, 2017, 43(6): 562-571.
|
| [37] |
Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy [J]. J Clin Invest, 2016, 126(8): 2933-2940.
|
| [38] |
Xu J, Jia X, Gu Y, et al. Vitamin D Reduces Oxidative Stress-Induced Procaspase-3/ROCK1 Activation and MP Release by Placental Trophoblasts [J]. J Clin Endocrinol Metab, 2017, 102(6): 2100-2110.
|
| [39] |
Burke SD, Zsengellér ZK, Khankin EV, et al. Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia [J]. J Clin Invest, 2016, 126(7): 2561-2574.
|